ArticlePain practice : the official journal of World Institute of Pain2022
Validity of the Central Sensitization Inventory compared with traditional measures of disease severity in fibromyalgia.
Article in Pain practice : the official journal of World Institute of Pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Psychometric properties of patient-reported outcome measures in chronic pain conditions with central sensitization- a systematic review and meta-analysis.Journal of patient-reported outcomes · 2025Pooled it
- Relationship Between Central Sensitization and Genetic Polymorphisms-A Case-Control Study in Fibromyalgia.European journal of pain (London, England) · 2026Trial
- Therapeutic Use of Virtual Reality for Patients With Fibromyalgia and Chronic Neck Pain: Randomized Controlled Trial.JMIR rehabilitation and assistive technologies · 2026Article
- Central Sensitization and Nociplastic Pain: Shared Mechanisms in Fibromyalgia, Osteoarthritis, and Inflammatory Arthritis.Journal of pain research · 2026Review
- Neuropathic pain and central sensitization in patients with rheumatoid arthritis attending a tertiary hospital.Advances in rheumatology (London, England) · 2025Article
- Evaluation of the presence of neuropathic pain and/or central sensitization in patients with radiographic axial spondyloarthritis followed at a tertiary hospital.Advances in rheumatology (London, England) · 2025Observational
- Central Sensitization Syndromes and Trauma: Mediating Role of Sleep Quality, Pain Catastrophizing, and Emotional Dysregulation Between Post-Traumatic Stress Disorder and Pain.Healthcare (Basel, Switzerland) · 2025Article
- Prevalence of central sensitisation associated symptoms and associations with treatment outcomes in surgical, interventional and injection-based treatment for patients with chronic spinal pain.SAGE open medicine · 2025Article
- Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies.Biomedicines · 2024Review
- Prevalence and Severity of Central Sensitization in Post-Polio Syndrome: Associations with Clinical Measures and Quality of Life.Annals of Indian Academy of Neurology · 2024Article
- Axial Spondyloarthritis: Reshape the Future-From the "2022 GISEA International Symposium".Journal of clinical medicine · 2022Review
- Validity of the Central Sensitization Inventory compared with traditional measures of disease severity in fibromyalgia.Pain practice : the official journal of World Institute of Pain · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe goal of this study was to explore additional evidence of convergent and discriminant validity of the Central Sensitization Inventory (CSI) in a large sample of subjects with fibromyalgia (FM).
methodsPatients were consecutively enrolled for a cross-sectional assessment comprehensive of three FM-specific measures (the revised Fibromyalgia Impact Questionnaire [FIQR], the modified Fibromyalgia Assessment Status [modFAS], and the Polysymptomatic Distress Scale [PDS]) and of CSI. To test the convergent validity, the Spearman's rho was used to measure the degree of correlation between the variables CSI and the FM-specific measures. To assess discriminant validity, CSI scores were grouped according to FIQR disease severity states, and differences between these groups studied with the Kruskal-Wallis test. Interpretative cutoffs were established with the interquartile reconciliation approach.
resultsThe study included 562 FM patients, 199 (35.4%) were classified as having central sensitization syndrome (CSI ≥40). CSI was largely correlated with modFAS (ρ = 0.580; p < 0.0001), FIQR (ρ = 0.542; p < 0.0001), and PDS (ρ = 0.518; p < 0.0001). The differences between the CSI scores in accordance with the FIQR were significant (p < 0.000001). CSI cutoffs proposed for FM: 21 between remission and mild severity, 30 between mild and moderate severity, 37 between moderate and severe disease, and 51 between severe and very severe disease.
conclusionThe current study successfully showed additional evidence of the convergent and discriminant validity of the CSI in FM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.